Kurt Redlich

TL;DR: The cellular and signalling pathways underlying, and strategies for therapeutically interfering with, the inflammatory loss of bone are discussed.

TL;DR: The task force defined the treatment target for SpA as remission or, alternatively, low disease activity, being aware that the evidence base is not strong and needs to be expanded by future research.

TL;DR: Recent data regarding the functions of AP-1 as a regulator of cytokine expression and an important modulator in inflammatory diseases such as rheumatoid arthritis, psoriasis and psoriatic arthritis are reviewed.

TL;DR: It is demonstrated that miR-155 is essentially involved in the adaptive and innate immune reactions leading to autoimmune arthritis, and therefore mi R-155 might provide a novel target for the treatment of patients with RA.

TL;DR: It is demonstrated that myostatin is highly expressed in the synovial tissues of RA subjects and of human tumor necrosis factor-α transgenic mice, a model for human RA, and is a potent therapeutic target for interfering with osteoclast formation and joint destruction in RA.